FDA Removes Key Warnings on Testosterone Therapy, Endorsing Use for Age-Related Low T

The short version: The U.S. Food and Drug Administration (FDA) has officially removed longstanding warnings that discouraged men from using testosterone replacement therapy (TRT) for age-related decline. In a sweeping regulatory shift announced alongside the Department of Health and Human Services (HHS), the agency also significantly loosened restrictions regarding prostate cancer and enlarged prostate risks.[1][2]

For over a decade, the official guidance suggested that treating the natural drop in testosterone that occurs as men age was medically unproven and potentially dangerous. Now, driven by a mountain of new clinical data, regulators are reversing course. The updated labeling effectively legitimizes TRT for age-related low testosterone, provided it is properly monitored by a physician.[3][4]

"During Men's Health Month, we are putting science back at the center of men's healthcare," HHS Secretary Robert F. Kennedy Jr. stated, noting that the updates give patients and physicians clearer information to make informed decisions and improve care for millions of American men.[1]

To understand why this matters, it helps to look at how testosterone functions. Testosterone is a vital hormone produced mainly in the testicles, responsible for maintaining muscle mass, bone density, libido, and overall energy levels. After age 30, a man's testosterone levels naturally decline by about 1% to 2% each year.[7]

When this decline causes clinical symptoms—such as chronic fatigue, erectile dysfunction, depression, or significant muscle loss—it is known as age-related hypogonadism. Previously, the FDA only fully endorsed TRT for men whose low testosterone was caused by specific medical conditions, such as genetic disorders or pituitary gland damage, leaving aging men in a regulatory gray area.[6][7]

The turning point for this policy shift was the TRAVERSE trial, a landmark study published in 2023. For years, the medical community harbored deep concerns that supplementing testosterone might trigger heart attacks or strokes. The FDA even mandated a "boxed warning"—its strictest safety alert—on TRT products in 2015 based on early, observational fears.[2][5]

The TRAVERSE trial was designed specifically to test that fear. It tracked over 5,200 men aged 45 to 80 who had preexisting cardiovascular disease or a high risk of developing it. Half received a daily transdermal testosterone gel, and half received a placebo.[4][5]

After nearly three years of monitoring, the results were definitive: there was no meaningful difference in major adverse cardiovascular events (MACE) between the two groups. Heart attacks, strokes, and cardiovascular deaths occurred in 7.0% of the testosterone group and 7.3% of the placebo group. The therapy did not break the heart.[2][5]

Based on these findings, the FDA removed the cardiovascular boxed warning in early 2025. Now, the agency has taken the final step by removing the "limitation of use" clause that explicitly questioned the safety and efficacy of TRT for age-related hypogonadism.[2][4]

The second major pillar of the FDA's update addresses the prostate. For decades, a pervasive medical belief held that testosterone therapy was "fuel for the fire" when it came to prostate cancer. Consequently, TRT labels warned against use in men with any known or suspected prostate cancer.[3][6]

Modern urological research has dismantled that assumption. Extensive reviews of randomized controlled trials and epidemiological data have consistently shown that TRT does not increase the risk of developing prostate cancer.[1][3]

Under the new FDA guidance, testosterone therapy is now contraindicated only for men with metastatic prostate cancer—cancer that has spread beyond the prostate to other parts of the body. For men with a history of localized, low-grade prostate cancer, the door is now open to discuss TRT with their doctors.[3][6]

The agency also revised its warnings regarding benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. Previous labels warned that TRT could worsen urinary symptoms associated with BPH, such as frequent urination or a weak stream.[1][6]

The FDA's review of the TRAVERSE trial and other data found no evidence that TRT worsens symptoms in men with mild to moderate BPH. While men with severe urinary symptoms are still advised to proceed with caution and require close monitoring, the blanket warning has been lifted.[1][3]

What does this mean for the average patient? Practically, it removes the stigma and the regulatory hurdles associated with seeking treatment for age-related decline. Physicians now have the explicit backing of federal health authorities to prescribe TRT based on a patient's symptoms and blood work, rather than having to navigate around outdated label limitations.[4][6]

However, experts emphasize that this is not a free pass for unregulated use. Testosterone therapy is a serious medical commitment. It shuts down the body's natural testosterone production, meaning that once a patient starts, stopping can lead to a severe crash in hormone levels that takes months to recover from.[7]

Furthermore, while the risk of heart attack is not elevated, TRT is not entirely without side effects. The TRAVERSE trial did note slight increases in the risk of atrial fibrillation (irregular heartbeat) and pulmonary embolism (blood clots in the lungs). The FDA also recently added warnings about potential increases in blood pressure for some patients.[5][7]

The most practical takeaway for men experiencing symptoms of low testosterone is to get tested. A proper diagnosis requires at least two separate morning blood tests showing total testosterone levels below 300 ng/dL, combined with clinical symptoms.[5][6]

Lifestyle factors should also be evaluated before starting lifelong hormone therapy. Weight loss, high-intensity aerobic exercise, strength training, and improved sleep can all naturally boost testosterone levels and alleviate symptoms without the need for medication.[7]

Ultimately, the FDA's decision marks a maturation in the field of men's health. By aligning policy with rigorous clinical evidence, regulators are acknowledging that testosterone is a critical marker of male health and longevity, and that treating its decline is a valid, safe medical practice when done correctly.[4][6]